Science Explorer Interactive view Map
Company · Glattbrugg · Switzerland

Vifor Pharma (Switzerland)

In research, Vifor Pharma (Switzerland) stands highest in Medicine (#10,607 of 17,978 worldwide) and Health Sciences (#13,463 of 20,462 worldwide), over all time.

viforpharma.com/enROR OpenAlex
World rank, 2022–2025
#18,058
of 28,054 · #15,849 all time
Rank in Switzerland
#123
of 220
Research works
309
▲ 142% vs 2013–17
Citations
6.3k
20.5 per fractional work
Top-10% rate
11.9%
record average 16.5%
Open access
47%
world 28%

What is Vifor Pharma (Switzerland) known for in research?

The fields where it stands highest, over all time, ranked among every institution above the floor in each field.

FieldWorld rankWhere that sitsTop-10% rateWorks
MedicineField #10,607 of 17,978 16.2%158
Health SciencesDomain #13,463 of 20,462 16.1%175

Each strip is that field’s whole ranked pool, with the notch where Vifor Pharma (Switzerland) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 1.25× its world share, 5 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 0.60× its world share, 3 worksBiochemistry, Geneti…Immunology and Microbiology: 3.71× its world share, 3 worksImmunology and Micro…Neuroscience: 0.93× its world share, 1 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 2.81× its world share, 1 worksPharmacology, Toxico…Chemistry: 0.31× its world share, 0 worksChemistryComputer Science: 0.02× its world share, 0 worksComputer ScienceEarth and Planetary Sciences: 0.31× its world share, 0 worksEarth and Planetary …Energy: 0.21× its world share, 0 worksEnergyEngineering: 0.27× its world share, 4 worksEngineeringEnvironmental Science: 0.10× its world share, 0 worksEnvironmental ScienceMaterials Science: 0.62× its world share, 2 worksMaterials SciencePhysics and Astronomy: 1.39× its world share, 3 worksPhysics and AstronomyDentistry: 0.53× its world share, 0 worksDentistryHealth Professions: 1.40× its world share, 3 worksHealth ProfessionsMedicine: 3.29× its world share, 55 worksMedicineNursing: 2.68× its world share, 1 worksNursingBusiness, Management and Accounting: 0.11× its world share, 0 worksBusiness, Management…Decision Sciences: 0.25× its world share, 0 worksDecision SciencesEconomics, Econometrics and Finance: 1.53× its world share, 3 worksEconomics, Econometr…Psychology: 0.05× its world share, 0 worksPsychologySocial Sciences: 0.08× its world share, 1 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 3.7×. Every wedge is a field page.

Who are the top researchers at Vifor Pharma (Switzerland)?

Ranked on the composite score, Isabelle Morin, Amandine Perrin and Peter Rutherford lead among researchers whose main affiliation is Vifor Pharma (Switzerland).

  1. 1 Isabelle Morin Switzerland · #996,041 worldwide 6 citations · 15 works
  2. 2 Amandine Perrin Switzerland · #1,027,013 worldwide 2 citations · 16 works
  3. 3 Peter Rutherford Switzerland · #1,417,838 worldwide 2 citations · 21 works
  4. 4 A Ramírez de Arellano Serna Switzerland · #1,547,098 worldwide 2 citations · 22 works
All ranked researchers at Vifor Pharma (Switzerland)

Which keywords describe research at Vifor Pharma (Switzerland)?

By fractional works in 2022–2025, weighted toward what it does more of than the world: Heart Failure, Chronic Kidney Disease, Inflammation, Diagnosis, Anemia, Cardiovascular Disease, Iron Deficiency and Erythropoiesis.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Heart Failure10▲ 26×9 topics
  2. Inflammation10▲ 5.4×20 topics
  3. Epidemiology10▲ 2.8×22 topics
  4. Chronic Kidney Disease10▲ 46×6 topics
  5. Diagnosis8▲ 9.8×10 topics
  6. Anemia8▲ 91×4 topics
  7. Cardiovascular Disease7▲ 7.5×12 topics
  8. Iron Deficiency7▲ 149×2 topics
  9. Oxidative Stress6▲ 4.5×12 topics
  10. Quality of Life6▲ 5.1×8 topics
  11. Erythropoiesis6▲ 115×2 topics
  12. Treatment6▲ 5.6×10 topics
  13. Hepcidin5▲ 155×1 topic
  14. Iron Regulation5▲ 155×1 topic
  15. Immune Dysregulation5▲ 74×2 topics
  16. Hyperkalemia5▲ 382×1 topic
  17. Management5▲ 7.0×7 topics
  18. Renin-Angiotensin-Aldosterone System Inhibitors5▲ 382×1 topic
  19. Autoantibodies5▲ 23×6 topics
  20. Filaggrin4▲ 99×1 topic
  21. Skin Microbiome4▲ 99×1 topic
  22. Guidelines4▲ 9.8×4 topics
  23. Autoimmune3▲ 65×2 topics
  24. Glomerular Diseases3▲ 94×1 topic
  25. Nephrotic Syndrome3▲ 94×1 topic
  26. Rituximab3▲ 20×2 topics
  27. Chronic Spontaneous Urticaria2▲ 129×1 topic
  28. Immune System2▲ 12×4 topics
  29. Primary Care2▲ 7.5×4 topics
  30. Urticaria2▲ 129×1 topic
  31. Clinical Features2▲ 75×2 topics
  32. Nutrition2▲ 6.1×3 topics
  33. TGF-ß2▲ 18×2 topics
  34. ANCA-associated2▲ 106×1 topic
  35. B-Type Natriuretic Peptide2▲ 55×1 topic
  36. Hospital Readmission2▲ 55×1 topic
  37. Vasculitides2▲ 106×1 topic
  38. Sickle-cell Disease2▲ 59×1 topic
  39. Thalassemia2▲ 59×1 topic
  40. Chronic Conditions2▲ 35×2 topics

Which research topics does Vifor Pharma (Switzerland) publish most on?

By volume in 2022–2025: Iron Metabolism and Disorders, Potassium and Related Disorders, Dermatology and Skin Diseases and Renal Diseases and Glomerulopathies.

Iron Metabolism and Disorders: 5 fractional worksPotassium and Related Disorders: 5 fractional worksDermatology and Skin Dis…4Dermatology and Skin Diseases: 4 fractional worksRenal Diseases and Glome…3Renal Diseases and Glomerulopathies: 3 fractional worksUrticaria and Related Conditions: 2 fractional worksVasculitis and related conditions: 2 fractional worksHeart Failure Treatment …2Heart Failure Treatment and Management: 2 fractional worksHemoglobinopathies and Related Disorders: 2 fractional worksPsoriasis: Treatment and Pathogenesis: 2 fractional worksOtitis Media and Relapsing Polychondritis: 2 fractional works
HematologyPulmonary and Respiratory MedicineDermatologyNephrology4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Iron Metabolism and Disorders Hematology 5 works
  2. 2 Potassium and Related Disorders Pulmonary and Respiratory Medicine 5 works
  3. 3 Dermatology and Skin Diseases Dermatology 4 works
  4. 4 Renal Diseases and Glomerulopathies Nephrology 3 works
  5. 5 Urticaria and Related Conditions Rheumatology 2 works
  6. 6 Vasculitis and related conditions Pulmonary and Respiratory Medicine 2 works
  7. 7 Heart Failure Treatment and Management Cardiology and Cardiovascular Medicine 2 works
  8. 8 Hemoglobinopathies and Related Disorders Genetics 2 works
  9. 9 Psoriasis: Treatment and Pathogenesis Immunology 2 works
  10. 10 Otitis Media and Relapsing Polychondritis Rheumatology 2 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available47.0%not open53.0%

World: 28% of research is openly available.

with international co-authors54.6%domestic only45.4%

World: 19% is written across borders.

How has Vifor Pharma (Switzerland)'s research output changed?

Output in 2018–2022 was 142% higher than in 2013–2017.

1990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.